MedPath

Teriflunomide

Generic Name
Teriflunomide
Brand Names
Aubagio, Teriflunomide Accord, Teriflunomide Mylan
Drug Type
Small Molecule
Chemical Formula
C12H9F3N2O2
CAS Number
163451-81-8
Unique Ingredient Identifier
1C058IKG3B

Overview

Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

Background

Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.

Indication

Used in the treatment of relapsing forms of multiple sclerosis (MS).

Associated Conditions

  • Multiple Sclerosis

FDA Approved Products

Teriflunomide
Manufacturer:AIZANT DRUG RESEARCH SOLUTIONS PVT LTD
Route:ORAL
Strength:7 mg in 1 1
Approved: 2023/02/22
NDC:69025-129
Teriflunomide
Manufacturer:Teva Pharmaceuticals, Inc.
Route:ORAL
Strength:7 mg in 1 1
Approved: 2023/03/14
NDC:0480-3157
Teriflunomide
Manufacturer:Mylan Pharmaceuticals Inc.
Route:ORAL
Strength:7 mg in 1 1
Approved: 2022/08/24
NDC:0378-0627
teriflunomide
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:ORAL
Strength:7 mg in 1 1
Approved: 2023/01/30
NDC:68462-423
Teriflunomide
Manufacturer:MSN LABORATORIES PRIVATE LIMITED
Route:ORAL
Strength:7 mg in 1 1
Approved: 2019/09/24
NDC:69539-315

Singapore Approved Products

AUBAGIO FILM-COATED TABLETS 14mg
Manufacturer:Opella Healthcare International SAS
Form:TABLET, FILM COATED
Strength:14.0mg
Online:Yes
Approved: 2015/08/31
Approval:SIN14841P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath